Iran's pharmaceutical market has entered a state of limbo after the re-imposition of sanctions halted the upswing momentum after their removal in 2016. The country's pharmaceutical expenditure valued at IRR90,803bn (USD2.26bn) in 2017. A lack of quality and reliable information is a problem associated with assessing Iran's pharmaceutical market and there is no data available regarding the split between patented and generic medicines. Due to the now-removed international sanctions, generic medicines have commanded the highest market share, and this will remain so at least over the short-to-medium term. Per capita spending on pharmaceuticals was a mere USD28 in 2017, among the lowest regionally.

Key View

SWOT

Industry Forecast

Industry Risk/Reward Index

Regulatory Development

Market Overview

Competitive Landscape

Company Profile

Iran Demographic Outlook 

Pharmaceuticals & Healthcare Glossary 

Pharmaceuticals & Healthcare Methodology